Keyphrases
Hepatitis C Virus Inhibitors
100%
Genotype 1
100%
Recombinant Genotypes
100%
NS5A Inhibitor
100%
Recombinant
100%
Genotype 3
100%
Combination Treatment
100%
Genotype 2a
100%
Virus
100%
JFH1
60%
Hepatitis C Virus
40%
Culture System
40%
Resistance mutations
40%
Adaptive mutation
40%
Combination Therapy
40%
NS3/4A Protease
40%
Genotype
20%
Low Sensitivity
20%
High Efficacy
20%
Focus-forming Units
20%
Online Treatment
20%
Supernatant
20%
Differential Sensitivity
20%
Specific Analysis
20%
Genetic Parameters
20%
Virologic Suppression
20%
Drug Concentration
20%
Infectivity Titer
20%
Viral Escape
20%
Response Profiles
20%
Resistance Selection
20%
Treatment Combination
20%
NS5A
20%
BMS-790052
20%
NS5B
20%
3′-untranslated Region (3′-UTR)
20%
Concentration-response
20%
Huh7.5 Cells
20%
Viral Life Cycle
20%
Drug Treatment
20%
Synergism
20%
Amino Acids
20%
Immunology and Microbiology
Hepatitis C Virus
100%
Virus
100%
NS5A Inhibitors
100%
Titer
20%
Recombinant Virus
20%
Synergism
20%
Concentration Response
20%
Virotherapy
20%
Amino Acid
20%
NS5B
20%
Viral Life Cycle
20%
NS5A
20%
Untranslated Region
20%
Drug Concentration
20%
Drug Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Daclatasvir
60%
Asunaprevir
60%
H 77
40%